CONNECTA Therapeutics

📍 Barcelona, Spain🗓 Founded 2019👥 6 employees💰 Last funded Sep 2020
Biotechnology Research🌐 connectatherapeutics.com
Website LinkedIn
CONNECTA Therapeutics S.L. is a biotechnology company that develops new treatments for CNS unmet medical needs. The company is initially focus on the clinical development of a new “first-in-class” molecule for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are no therapeutic interventions currently available. The molecule was discovered after evaluating more than 30 molecular and cellular targets. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Spain
1
Frequently asked questions
Who invested in CONNECTA Therapeutics?
CONNECTA Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did CONNECTA Therapeutics last raise funding?
The most recent investment in CONNECTA Therapeutics recorded on gritt.io was in September 2020.
When was CONNECTA Therapeutics founded?
CONNECTA Therapeutics was founded in 2019.
What industry is CONNECTA Therapeutics in?
CONNECTA Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is CONNECTA Therapeutics based?
CONNECTA Therapeutics is headquartered in Barcelona, Spain.